» Articles » PMID: 17579360

A Single Mutation in the GALC Gene is Responsible for the Majority of Late Onset Krabbe Disease Patients in the Catania (Sicily, Italy) Region

Overview
Journal Hum Mutat
Specialty Genetics
Date 2007 Jun 21
PMID 17579360
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

A high proportion of patients with late onset forms of Krabbe disease is observed in a region north of Catania in Sicily. Molecular analysis in five families from this region shows that this condition is mainly due to a not previously described p.Gly41Ser substitution in the GALC gene that abolishes catalytic activity of the galactocerebrosidase enzyme, as shown by expression studies. Three patients were homozygous for this mutation, the other two were heterozygous, one with a frameshift mutation and one with a missense mutation on the second allele. Therefore, the mutation must be a mild one since it leads to late onset disease in all patients. In addition, it is on a unique haplotype indicating that it represents a founder mutation. This is also supported by the fact that the mutation was not found in three late onset patients from other regions in Sicily, in whom four novel mutations were identified.

Citing Articles

CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β-Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease.

Rebiai R, Rue E, Zaldua S, Nguyen D, Scesa G, Jastrzebski M Front Mol Neurosci. 2022; 15:896314.

PMID: 35620447 PMC: 9127972. DOI: 10.3389/fnmol.2022.896314.


Achievements and beyond: Scientific trajectory of Professor Mohammad A. Rafi.

Omidi Y, Alavi A Bioimpacts. 2021; 11(1):1-4.

PMID: 33469502 PMC: 7803920. DOI: 10.34172/bi.2021.01.


Genotype and phenotype classification of 29 patients affected by Krabbe disease.

Madsen A, Wibrand F, Lund A, Ek J, Duno M, Ostergaard E JIMD Rep. 2019; 46(1):35-45.

PMID: 31240153 PMC: 6498822. DOI: 10.1002/jmd2.12007.


Cell-based high-throughput screening identifies galactocerebrosidase enhancers as potential small-molecule therapies for Krabbe's disease.

Jang D, Ye W, Guimei T, Solomon M, Southall N, Hu X J Neurosci Res. 2016; 94(11):1231-45.

PMID: 27638606 PMC: 5328637. DOI: 10.1002/jnr.23875.


Biochemical, cell biological, pathological, and therapeutic aspects of Krabbe's disease.

Won J, Singh A, Singh I J Neurosci Res. 2016; 94(11):990-1006.

PMID: 27638584 PMC: 5812347. DOI: 10.1002/jnr.23873.